Patient Portal
    Text START to:+1 (770) 243-5753
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    Trusted by over 10K subscribers
    Free & discreet shipping on all prescriptions
    Affordable pricing with no hidden fees
    FDA-regulated pharmacies
    100% online process
    HomeMedication GuideBremelanotide safety
    Melanocortin receptor agonistFDA-Approved

    Bremelanotide (PT-141): Patient Information & Safety Notes

    Also known as PT-141, PT141, Vyleesi

    Other names: pt-141, pt141, vyleesi, bremelanotide-pt-141

    Bremelanotide (PT-141) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts on melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system to modulate sexual desire. It is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.

    FDA-approved as Vyleesi for premenopausal women with acquired, generalized HSDD. Use in men or postmenopausal women is off-label and is not an FDA-approved indication.
    Reviewed by the OmniRx Health clinical team•Last reviewed Jul 4, 2026

    In plain language

    What Bremelanotide is used for

    • FDA-approved: hypoactive sexual desire disorder (HSDD) in premenopausal women
    • Use in men or postmenopausal women is off-label and not FDA-approved

    Taking this medicine

    How it is administered

    • Subcutaneous injection

    Read before you decide

    Risks and precautions

    Risks and warnings

    • Nausea (most common; may require anti-nausea medication)
    • Flushing
    • Headache
    • Transient blood pressure increase
    • Can slow gastric emptying and reduce the absorption or effectiveness of oral medicines, including oral naltrexone products

    Who should not take it

    • Uncontrolled hypertension or known cardiovascular disease
    • Pregnancy (fetal harm is possible) or breastfeeding

    Common questions

    Patient questions

    Is bremelanotide (PT-141) FDA-approved?

    Yes, but only for premenopausal women with hypoactive sexual desire disorder (HSDD), under the brand name Vyleesi. Use in men or postmenopausal women is off-label. A licensed provider must determine if it is appropriate for you.

    How is bremelanotide different from sildenafil (Viagra)?

    Bremelanotide acts centrally on brain receptors to influence desire and arousal, while sildenafil acts peripherally on blood vessel tone to support erection. They target different aspects of sexual function.

    Explore treatment hubs

    Sexual Wellness

    This information is educational — not medical advice.

    This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.

    Have medication questions?

    A licensed OmniRx provider can review your health history and medication list. Availability and treatment options are determined individually.

    Sources & References

    Learn more about where our data comes from and how we write and review medical content.